EXJADE Effectively Treats Iron Toxicity
Across Aplastic and Other Anemias

EXJADE has shown efficacy increasing the removal of excess iron in the body. In 2007, a clinical study showed patients with Diamond-Blackfan and other anemias experienced substantial iron excretion.1

EXJADE Increases Iron Excretion in Patients
With Rare Anemias1
EXJADE Increases Iron Excretion in Patients with Rare Anemias

Prospective phase 2 trial evaluating safety and efficacy of EXJADE in patients (N=184) aged 3-81 years with transfusion-dependent anemias including β-thalassemia, myelodysplastic syndrome, Diamond-Blackfan, and other
rare anemias.

Iron Excretion Increases In Patients With Other Rare Anemias

Effective in reducing iron toxicity across a range of clinical parameters

Based on established testing standards, EXJADE has been shown as an effective iron chelator for those with aplastic and other anemias suffering from iron toxicity.1,2,3

These standards include:

  • Serum Ferritin
  • Liver Iron Concentration

EXJADE reduces iron toxicity in aplastic and other anemias

In several clinical trials, EXJADE has been shown to effectively treat iron toxicity in the following groups of anemia patients:


Answers to common questions about many aspects of EXJADE therapy.

Learn more


Several studies have demonstrated the safety of EXJADE.

Learn more